跳转至内容
Merck
CN

D-011

Supelco

1,3-二硝基甘油 溶液

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C3H6N2O7
CAS号:
分子量:
182.09
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

certified reference material

质量水平

形式

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in acetonitrile

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

pharmaceutical (small molecule)

格式

single component solution

储存温度

−20°C

SMILES字符串

OC(CO[N+]([O-])=O)CO[N+]([O-])=O

InChI

1S/C3H6N2O7/c6-3(1-11-4(7)8)2-12-5(9)10/h3,6H,1-2H2

InChI key

ASIGVDLTBLZXNC-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

1,3-二硝基甘油是药物血管扩张剂硝酸甘油的主要血浆代谢产物。该经认证的加标溶液®适用于药学研究或临床毒理学中基于色谱或质谱的应用。硝酸甘油用于治疗心脏病,例如心绞痛和慢性心力衰竭。

应用

  • Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system: This study presents a comprehensive analysis on the population pharmacokinetics of nitroglycerin, focusing on its behavior and the behavior of its metabolites following the use of a transdermal delivery system. The findings contribute to understanding the systemic availability and action of nitroglycerin from such systems, which could be relevant for 1,3-Dinitroglycerin given its structural and functional similarities (Auclair et al., 1998).
  • Novel pharmacokinetic modelling of transdermal nitroglycerin: This research explores advanced pharmacokinetic models that describe the absorption and action of nitroglycerin when administered through transdermal patches. Such models are crucial for developing effective transdermal delivery systems for similar compounds like 1,3-Dinitroglycerin (Auclair et al., 1998).
  • Bioequivalence Comparison of Two Drug-in-Adhesive Transdermal Nitroglycerin Patches: This study compares the bioequivalence of two transdermal patches delivering nitroglycerin, highlighting the critical factors in the design and performance of transdermal systems that could similarly apply to 1,3-Dinitroglycerin (Harrison et al., 1996).
  • Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis: Directly relevant to 1,3-Dinitroglycerin, this study examines its percutaneous absorption characteristics, offering insights into its potential applications in transdermal delivery systems (Ogiso et al., 1990).
  • Analysis of solutions containing glutathione and inorganic nitrite: application to nitroglycerin metabolism studies: While primarily focused on nitroglycerin, this analysis could provide secondary insights into the metabolic pathways and interactions of 1,3-Dinitroglycerin with biomolecules like glutathione, which is crucial for understanding its pharmacological effects (Curry et al., 1987).

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

FlameExclamation mark

警示用语:

Danger

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

WGK

WGK 2

闪点(°F)

closed cup

闪点(°C)

closed cup

法规信息

危险化学品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M Gumbleton et al.
Journal of pharmacokinetics and biopharmaceutics, 21(5), 515-532 (1993-10-01)
The organic nitrate 1,3-glyceryl dinitrate (1,3-GDN) is one of the primary dinitrate metabolites of the antianginal agent nitroglycerin (GTN). Investigational New Drug Approval was sought to administer oral solution doses of 1,3-GDN to a small number (n = 3) of
D T Lau et al.
Biochemical pharmacology, 43(10), 2247-2254 (1992-05-28)
The effects of sulfobromophthalein (SBP) and ethacrynic acid (ECA), both inhibitors of glutathione S-transferase (GST), or glyceryl trinitrate (GTN)-induced vasorelaxation were investigated in rabbit aortic strips. The aortic strips were pre-contracted with phenylephrine, followed by relaxation with 0.5 microM GTN
T Fujii et al.
Biological & pharmaceutical bulletin, 19(8), 1093-1096 (1996-08-01)
Nitroglycerin (GTN) has been used as the drug of choice in the treatment of angina pectoris. It has been shown that some glutathione S-transferases (GSTs) catalyze the metabolic conversion from GTN to glyceryl dinitrates (GDNs). In this study, we examined
R C Jewell et al.
Pharmaceutical research, 9(10), 1284-1289 (1992-10-01)
The FDA Cooperative Efficacy Study of transdermal nitroglycerin utilized a combination of marketed products over a wide dose range. Unfortunately, plasma nitroglycerin concentrations were not determined. The current study was conducted to assess plasma nitrate concentrations after transdermal doses of
B Auclair et al.
Therapeutic drug monitoring, 20(6), 607-611 (1998-12-16)
The purpose of this study was to assess the ability of our previously constructed pharmacokinetic (PK) model to describe nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN) plasma concentrations after a single-dose application of a GTN transdermal matrix delivery system. GTN

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门